Global Dermatitis Market, By Type (Contact Dermatitis, Atopic Dermatitis, Diaper Dermatitis, Nummular Dermatitis, Dyshidrotic Dermatitis, Perioral Dermatitis, Neurodermatitis, Seborrheic Dermatitis, Stasis Dermatitis), Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Topical Corticosteroids, Emollients, Topical Antiseptic, Others), Diagnosis (Blood Tests, Allergy Skin Test, Skin Biopsy), Route of Administration (Oral, Topical, Others), Dosage Form (Tablets, Ointments, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the dermatitis market is anticipated to grow rapidly during the forecast period. Atopic dermatitis affects roughly 31.6 million people in the United States as per the allergy asthma network 2020. Atopic dermatitis affects 15-20 percent of children and 1 to 3 percent of adults over the world. Additionally, continuously changing lifestyle results in the surging use of cosmetics, face creams, sunscreen and fluorinated toothpaste. Along with this, the prevalence rate of lifestyle or chronic diseases is high, including the growing use of topical and inhaled steroids. These are the causative factors increasing the risk of dermatitis. Hence this led to the high demand for dermatitis in the market.
Data Bridge Market Research analyses that the dermatitis market was valued at USD 5.92 billion in 2021 and is expected to reach USD 11.04 billion by 2029, registering a CAGR of 8.10% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Dermatitis is a term that encompasses a variety of illnesses, including skin inflammation. Most people's early stages of dermatitis are marked by red, dry, and itchy skin. More severe dermatitis might cause crusty scales, painful cracks, or fluid-filled blisters. Because numerous items can irritate the skin, a doctor will strive to narrow down the diagnosis to a specific type of dermatitis, even though most types of skin irritation and inflammation have comparable treatments.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Contact Dermatitis, Atopic Dermatitis, Diaper Dermatitis, Nummular Dermatitis, Dyshidrotic Dermatitis, Perioral Dermatitis, Neurodermatitis, Seborrheic Dermatitis, Stasis Dermatitis), Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Topical Corticosteroids, Emollients, Topical Antiseptic, Others), Diagnosis (Blood Tests, Allergy Skin Test, Skin Biopsy), Route of Administration (Oral, Topical, Others), Dosage Form (Tablets, Ointments, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark), Aurobindo Pharma (India), Lupin (India), Eli Lilly and Company (US), Boehringer Ingelheim International GmbH. (Germany), Bausch Health Companies Inc. (Canada), Bristol-Myers Squibb Company (US), AbbVie Inc. (US), Allergan (Ireland)
|
|
Market Opportunities
|
|
Dermatitis Market Dynamics
Drivers
- Surging prevalence rate of allergic reactions
The rising prevalence of allergic reactions, with food allergies playing a prominent role is estimated to enhance the dermatitis market's growth. According to a 2020 report from the Food Allergy Research and Education, 32 million Americans have food allergies, including 5.6 million children under the age of 18. Approximately 40% of children with food allergies are allergic to many foods.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of dermatitis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get chronic ailments, further estimated to enhance the market's growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the dermatitis market. Additionally, increasing environmental pollution and rising incidences of hormonal imbalances will expand the dermatitis market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the dermatitis market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the dermatitis market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the dermatitis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This dermatitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dermatitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Dermatitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Dermatitis Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems were severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations had a negative impact on the market of dermatitis in recent months.
Recent Development
- In May 2020, Sanofi had announced the U.S. Food and Drug Administration (FDA) approval for Dupixent (dupilumab). It is approved as a first biologic medicine for children aged 6 to 11 years suffering from moderate-to-severe atopic dermatitis. When compared to TCS alone, Dupixent + topical corticosteroids (TCS) resulted in more than twice as many children having clear or nearly clear skin and more than four times as many children having itch relief in the crucial trial. Three-quarters of Dupixent patients saw a 75 percent or greater improvement in total illness, with an average improvement of around 80 percent.
Global Dermatitis Market Scope
The dermatitis market is segmented on the basis of type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Contact Dermatitis
- Atopic Dermatitis
- Diaper Dermatitis
- Nummular Dermatitis
- Dyshidrotic Dermatitis
- Perioral Dermatitis
- Neurodermatitis
- Seborrheic Dermatitis
- Stasis Dermatitis
Treatment
- Antibiotics
- Antihistamines
- Calcineurin Inhibitors
- Topical Corticosteroids
- Emollients
- Topical Antiseptic
- Others
Diagnosis
- Blood Tests
- Allergy Skin Test
- Skin Biopsy
Dosage form
- Tablets
- Ointments
- Others
Route of Administration
- Oral
- Topical
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Dermatitis Market Regional Analysis/Insights
The dermatitis market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the dermatitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the perioral dermatitis treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.
Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period of 2022-2029 due to the increasing cases of dermatitis diseases and rising investment in the healthcare sector. Also, growing government support and rising level of disposable income will propel the market's growth rate.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Dermatitis Market Share Analysis
The dermatitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dermatitis market.
Some of the major players operating in the dermatitis market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France), Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- AstraZeneca (UK)
- Johnson & Johnson (US)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- LEO Pharma A/S (Denmark)
- Aurobindo Pharma (India)
- Lupin (India)
- Eli Lilly and Company (US)
- Boehringer Ingelheim International GmbH. (Germany)
- Bausch Health Companies Inc. (Canada)
- Bristol-Myers Squibb Company (US)
- AbbVie Inc. (US)
- Allergan (Ireland)
SKU-